BioNTech and DualityBio Receive FDA Breakthrough Therapy
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced...
Source: globenewswire.com
Page 24 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Roche Group Today - Breaking & Trending Today
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
– If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure – – Interim analysis results from first-of-its-kind Phase III...
Source: marketscreener.com
Roche : Invitation to Roche's Full Year Results 2023 Presentation -December 19, 2023 at 04:24 am EST
Roche will publish its Full Year Results of 2023 prior to the opening of the Swiss Stock Exchange on Thursday,1 February2024. 07:00 CET / 06:00 GMT / 01:00 AM EST...
Source: marketscreener.com
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
Healthcare professionals greatly value navify Tumor Board for improving tumour board meeting experiences, offering a holistic view of data, facilitating multidisciplinary team collaboration and...
Source: marketscreener.com
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...
Source: marketscreener.com